Biotech company developing a new class of potent and scalable active off-the-shelf cancer vaccine
PDC*line Pharma has raised €26M across 2 funding rounds from 9 investors, most recently a round in Jan 2024. Based in Liege, Belgium; active in Healthtech. Data as of 7 Aug 2026.
Timing: overdue vs cohort gap · momentum down. Funding-only estimates, not predictions and not investment advice — see signals.
| Date |
|---|
| Stage |
|---|
| Amount |
|---|
| Investors |
|---|
| 2024-01-18 | Other | €8.1M | — | View deal → |
| 2021-12-06 | Series B | €18M | Alpha Holdings,Brain Asset Management,Hansongneotech Co.,Korea Investment Partners,Noshaq Group,Sambrinvest+3 more | View deal → |
